In ambulatory heart failure patients, elevated BNP, ANP, and Big Endothelin-1 each independently correlated with disease severity and were associated with different clinical features of heart failure.
Complementary markersBNP/ANP reflected cardiac overload while Big Endothelin-1 reflected vascular/renal dysfunction — different peptides reveal different heart failure mechanisms
What the researchers found
BNP, ANP, and Big Endothelin-1 each independently correlated with heart failure severity but reflected different pathophysiological aspects — cardiac volume overload versus vascular/renal dysfunction — providing complementary clinical information.
Why it matters
Heart failure is a complex syndrome with multiple contributing mechanisms. Using multiple peptide biomarkers provides a more complete picture of each patient's specific pathophysiology, enabling more personalized treatment.
How the study worked
Cross-sectional cohort study in ambulatory heart failure patients. Plasma BNP, ANP, and Big Endothelin-1 correlated with clinical parameters including NYHA class, echocardiographic measurements, and renal function.
What this study cannot tell us
Cross-sectional design cannot establish causation. Ambulatory patients may not represent the full heart failure spectrum. Specific cutoff values not established.
How to read the evidence
Moderate evidence from a well-characterized outpatient heart failure cohort with multiple simultaneous biomarker measurements.
When this study was published
Published in 2000. Multi-marker approaches in heart failure have evolved, with NT-proBNP now standard and endothelin pathway drugs (bosentan) in clinical use.
The bigger picture
Precision medicine in heart failure requires understanding each patient's specific disease mechanisms. Multi-peptide biomarker panels can distinguish between cardiac, vascular, and renal contributions to heart failure.
Questions still open
- Should multi-peptide panels replace single-marker testing in heart failure?
- Can serial multi-marker monitoring guide treatment adjustments?
- Do different biomarker profiles predict different treatment responses?
Common questions
Why measure multiple peptides for heart failure?
Does this change treatment?
Read the original research
Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. IN-CHF Investigators.
Italian heart journal : official journal of the Italian Federation of Cardiology, 1(4), 282-8
Citation
Masson, S; Gorini, M; Salio, M; Lucci, D; Latini, R; Maggioni, A P. (2000). Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. IN-CHF Investigators.. Italian heart journal : official journal of the Italian Federation of Cardiology, 1(4), 282-8.